Q-omics provides the consensus-scored NBPF6 profile across patient tissues and cancer cell-line models. NBPF6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NBPF6 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, NBPF6 RNA expression shows 6,127 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, and BRCA as cancer lineages where NBPF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF6 survival associations across molecular data types. NBPF6 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF6 RNA expression–survival associations across cancer types. High NBPF6 expression shows unfavorable associations in LIHC, DLBC, CESC, KICH and CHOL, but favorable associations in BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NBPF6 RNA expression.
This table summarizes NBPF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF6 shows lower tumor expression in KICH and higher tumor expression in BRCA, PAAD, UCEC, LUSC and LUAD. The BRCA box plot shows higher NBPF6 RNA expression in tumor versus normal tissue (log2 FC = +0.920, t-test p < 0.001).
This table shows molecular features associated with NBPF6 in patient tissues and cancer cell lines. In patient samples, NBPF6 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
